Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Michael S. Finnin, Jill R. Donigian, Alona Cohen et al. · Nature · 1999 · 1.7K citations

Life Sciences, Medicinal Chemistry, Molecular Biology +12

Acute Myeloid Leukemia

Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations

Medicine, Oncology, Radiation Oncology +14

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-<i>N</i>-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

Xiong Cai, Hai-Xiao Zhai, Jing Wang et al. · Journal of Medicinal Chemistry · 2010 · 264 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard et al. · Journal of Medicinal Chemistry · 2011 · 198 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Yongchao Wang, Warren Fiskus, Daniel G. Chong et al. · Blood · 2009 · 177 citations · Full text

Medicine, Oncology, Pharmacology +16